Study protocol: a pragmatic, cluster-randomized controlled trial to evaluate the effect of implementation of the Truenat platform/MTB assays at primary health care clinics in Mozambique and Tanzania (TB-CAPT CORE)

V. N. Leukes,J. Hella,I. Sabi,M. Cossa,C. Khosa,B. Erkosar,C. Mangu,E. Siyame,B. Mtafya,A. Lwilla,S. Viegas,C. Madeira,A. Machiana,J. Ribeiro,A. L. Garcia-Basteiro,F. Riess,D. Elísio,M. Sasamalo,G. Mhalu,C. M. Denkinger,M. D. M. Castro,S. Bashir,S. G. Schumacher,E. Tagliani,A. Malhotra,D. Dowdy,C. Schacht,J. Buech,D. Nguenha,N. Ntinginya,M. Ruhwald,A. Penn-Nicholson,K. Kranzer,TB-CAPT Consortium
DOI: https://doi.org/10.1186/s12879-023-08876-8
IF: 3.7
2024-01-20
BMC Infectious Diseases
Abstract:In 2020, the WHO-approved Molbio Truenat platform and MTB assays to detect Mycobacterium tuberculosis complex ( MTB ) and resistance to rifampicin directly on sputum specimens. This primary health care center-based trial in Mozambique and Tanzania investigates the effect of Truenat platform/MTB assays (intervention arm) combined with rapid communication of results compared to standard of care on TB diagnosis and treatment initiation for microbiologically confirmed TB at 7 days from enrolment.
infectious diseases
What problem does this paper attempt to address?